John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Horace Mann Educators
HMN
$2.07B
| $3.52M | 0.01% |
95,224
-29,635
| -24% | -$1.05M |
|
|
DENN
1127
DELISTED
Denny's
DENN
| $3.51M | 0.01% |
392,236
+205,123
| +110% | +$2.01M |
|
|
STR
1128
DELISTED
Sitio Royalties
STR
| $3.51M | 0.01% |
141,971
+128,513
| +955% | +$2.89M |
|
1129
Nu Skin
NUS
$232M
| $3.5M | 0.01% |
253,318
-89,377
| -26% | -$1.4M |
|
1130
Coherus Oncology
CHRS
$210M
| $3.49M | 0.01% |
1,462,013
+11,661
| +0.8% | +$28.7K |
|
1131
Donnelley Financial Solutions
DFIN
$1.17B
| $3.49M | 0.01% |
56,270
+40,770
| +263% | +$2.55M |
|
1132
Pegasystems
PEGA
$5.64B
| $3.48M | 0.01% |
107,580
-32,756
| -23% | -$919K |
|
|
SEI
1133
Solaris Energy Infrastructure
SEI
$3.52B
| $3.48M | 0.01% |
400,844
-112,063
| -22% | -$880K |
|
1134
Encore Capital Group
ECPG
$2.19B
| $3.47M | 0.01% |
76,163
+18,094
| +31% | +$892K |
|
1135
Warby Parker
WRBY
$3.24B
| $3.46M | 0.01% |
253,917
+97,838
| +63% | +$1.3M |
|
1136
Service Corp International
SCI
$11.5B
| $3.45M | 0.01% |
+46,500
| New | +$3.28M |
|
1137
AngioDynamics
ANGO
$652M
| $3.45M | 0.01% |
587,098
-68,215
| -10% | -$405K |
|
1138
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$32.9B
| $3.44M | 0.01% |
+31,570
| New | +$3.43M |
|
1139
Matthews International
MATW
$662M
| $3.44M | 0.01% |
110,557
-28,373
| -20% | -$878K |
|
|
REVG
1140
DELISTED
REV Group
REVG
| $3.43M | 0.01% |
155,271
-13,507
| -8% | -$253K |
|
1141
Blend Labs
BLND
$355M
| $3.43M | 0.01% |
1,054,438
+785,565
| +292% | +$2.12M |
|
|
KVAC
1142
DELISTED
Keen Vision Acquisition Corp
KVAC
| $3.4M | 0.01% |
325,000
| – | – |
|
|
TPC
1143
Tutor Perini Cor
TPC
$4.64B
| $3.4M | 0.01% |
234,850
-2,831
| -1% | -$28.9K |
|
1144
AdaptHealth
AHCO
$751M
| $3.39M | 0.01% |
294,346
+201,877
| +218% | +$1.71M |
|
1145
Eldorado Gold
EGO
$12.1B
| $3.38M | 0.01% |
240,550
-461,811
| -66% | -$5.61M |
|
1146
Hope Bancorp
HOPE
$1.78B
| $3.38M | 0.01% |
293,803
-9,317
| -3% | -$105K |
|
|
BRSP
1147
BrightSpire Capital
BRSP
$621M
| $3.36M | 0.01% |
487,028
-17,693
| -4% | -$124K |
|
1148
Teekay
TK
$1.17B
| $3.35M | 0.01% |
460,408
-435,072
| -49% | -$3.41M |
|
1149
Target
TGT
$77.2B
| $3.35M | 0.01% |
18,888
-604,216
| -97% | -$91.9M |
|
1150
CRISPR Therapeutics
CRSP
$5.52B
| $3.34M | 0.01% |
49,058
-35,973
| -42% | -$2.58M |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.